Analisis Drug Related Problems Pasien Depresi di Rumah Sakit Jiwa Marzoeki Mahdi Bogor Triwulan I 2024
DOI:
https://doi.org/10.30595/pharmacy.v22i1.25315Keywords:
Antidepresan, Drug Related Problems, DepresiAbstract
Masalah terkait obat lazim terjadi pada pengobatan jiwa termasuk depresi yang dapat menyebabkan morbiditas dan mortalitas pasien. Tujuan penelitian ini untuk menganalisis kejadian DRP pada pasien depresi. Penelitian ini merupakan studi cross sectional dengan pengambilan data secara prospektif. Subyek penelitian adalah seluruh pasien depresi di poliklinik Cemas & Depresi periode Januari sampai Maret 2024 yang memenuhi kriteria inklusi. Pada penelitian ini dilakukan analisis faktor yang diprediksi berpotensi menyebabkan DRP terdiri dari karakteristik demografi dan klinis menggunakan uji regresi logistik. Analisis DRP menggunakan Pharmaceutical Care Network Europe (PCNE) V9.1. Jumlah sampel penelitian sebanyak 173 pasien. Pada penelitian ini pasien jenis kelamin terbanyak yaitu perempuan (68,2%); rata-rata usia 38,4 tahun; dengan pendidikan tinggi (72,8%) dan tidak bekerja (57,2%). Lama pengobatan rata-rata 22 bulan; jumlah obat rata-rata 3 item; dan tanpa penyakit penyerta (86.1%). Antidepresan yang paling sering diresepkan adalah sertralin (62,9%) dan sebanyak 91% merupakan terapi kombinasi dengan kombinasi terbanyak adalah sertralin-clobazam-lorazepam (22%). Terdapat 655 DRP dengan 194 DRP aktual (29,6%) dan 461 DRP Potensial (70,4%). Secara keseluruhan DRP paling banyak terkait potensi interaksi obat sebanyak 59%; durasi pengobatan terlalu lama sebanyak 21,2%; terkait kepatuhan minum obat sebanyak 8,4%; dosis obat terlalu rendah sebanyak 6,1% dan penyebab lain sebanyak 5,3%. Antidepresan yang sering menyebabkan DRP adalah amitriptilin 35,7%. Obat yang sering menyebabkan DRP adalah lorazepam sebanyak 36,4% dan clobazam 33,8%. Karakteristik pasien yang berpengaruh signifikan (p value < 0,05) terhadap kejadian DRP adalah usia (p value 0,035; odds ratio 1,044; 95% CI 1,003-1,087); jumlah obat (p value 0,000; odds ratio 3,206; 95% CI 1,951-5,268) dan lama pengobatan (p value 0,007; odds ratio 1,035; 95% CI 1,009-1,061).
References
Alshaikhmubarak FQ, Keers RN, Lewis PJ. 2023. Potential risk factors of drug-related problems in hospital-based mental health units: A systematic review, Drug Safety, 46, 19–37.
BPS. 2023. Statistik Pendidikan 2023. Jakarta, Badan Pusat Statistik.
Buckman JEJ, Saunders R, Stott J, Cohen ZD, Arundell LL, Eley TC. 2022. Socioeconomic indicators of treatment prognosis for adults with depression: A systematic review and individual patient data meta-analysis, JAMA Psychiatry, 79, 406–416.
Duan Y, Wei J, Geng W, Jiang J, Zhao X, Li T. 2019. The effect of short-term use of benzodiazepines on cognitive function of major depressive disorder patients being treated with antidepressants, Journal of Affective Disorders, 256, 1–7.
Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH. 2010. American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder, The American Journal of Psychiatry, 167, 9–118.
Gillman PK. 2007. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated, British Journal of Pharmacology, 151, 737–748.
Kemenkes RI. 2019. Infodatin Kesehatan Jiwa: Situasi Kesehatan Jiwa di Indonesia. Jakarta, Pusat Data dan Informasi Kementrian Kesehatan Republik Indonesia, 1-8.
Kementrian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/2197/2023 tentang Formularium Nasional. Jakarta: Kementrian Kesehatan RI. 2023.
Kementrian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/6485/2021 tentang Formularium Nasional. Jakarta: Kementrian Kesehatan RI. 2021.
Khushboo BS. 2017. Antidepressants: Mechanism of action, toxicity and possible amelioration, Journal of Applied Biotechnology & Bioengineering, 3(5).
Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. 2023. Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: A systematic review and meta-analysis, Psychological Medicine, 53(9),4064–4082.
Matthew AF, Martha S. 2007. Drug Information Handbook for Psychiatry. 6th Edition. Texas, Lexi-Comp Inc.
Nagappa A, Verupaksha D, Balkrishnan R, Bhandary P, Lalwani T, Mateti U. 2015. Assessment of drug-related problems in depressive patients, Perspectives in Clinical Research, 6(1), 58.
Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, 2019. Antidepressants plus benzodiazepines for adults with major depression, Cochrane Database of Systematic Reviews, 6(6), CD001026.
Pandarakalam JP. 2018. Challenges of treatment-resistant depression, Psychiatria Danubina Medicinska Naklada Zagreb, 30, 273–84.
Parker G, Brotchie H. 2010. Gender differences in depression, International Review of Psychiatry, 22, 429–436.
PCNE. 2020. Pharmaceutical Care Network Europe Association Classification for Drug Related Problems V9.1. 2020.
Regan CO, Kearney PM, Savva GM, Cronin H, Kenny RA. 2013. Age and sex differences in prevalence and clinical correlates of depression: First results from the Irish Longitudinal Study on ageing, International Journal of Geriatric Psychiatry, 28(12), 1280–1287.
Rogóz Z. 2013. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: Preclinical and clinical efficacy, Pharmacological Reports, 65(6), 1535–1544.
Sadock BJ, Samoon A, Sadock VA. 2019. Kaplan & Sadock’s Pocket Handbook of Clinical Psychiatry. Sixth edition. Philadelphia, Wolters Kluwer, 823-84.
Santarsieri D, Schwartz TL. 2015. Antidepressant efficacy and side-effect burden: A quick guide for clinicians, Drugs in Context, 4, 212290.
Treuer T, Liu CY, Salazar G, Kongsakon R, Jia F, Habil H, 2013. Use of antidepressants in the treatment of depression in Asia: Guidelines, clinical evidence, and experience revisited, Asia-Pacific Psychiatry, 5, 219–230.
WHO. 2008. The Global Burden of Disease: 2004 Update. Geneva, World Health Organization, 43.
Wolff J, Reißner P, Hefner G, Normann C, Kaier K, Binder H. 2021. Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders, PLoS One, 16(7).
Yustika D, Riki R, Adiatma YMS. 2020. Analisis faktor socioeconomic status (SES) terhadap kesehatan mental: Gejala depresi di Indonesia, Jurnal Ekonomi Kesehatan Indonesia. 5(2).
Zitman FG, Couvée JE. 2001. Chronic benzodiazepine use in general practice patients with depression: An evaluation of controlled treatment and taper-off - Report on behalf of the Dutch Chronic Benzodiazepine Working Group, British Journal of Psychiatry, 178(APR.), 317–324.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
